From: Comparing COVID-19-linked neurological complications with other viral infections
Neurologic disorders | COVID-19 SARS-CoV-2 infection 2019 | SARS SARS-CoV-1 infection 2003 | INFLUENZA H1N1 infection 2009 |
---|---|---|---|
Frequency | 2.8% (6/214) patients with acute cerebrovascular disease, Wuhan China [1] 13.8% (8/58) required intensive care, France [13] Globally, 93 patients with encephalopathy; 19 patients with Guillain-Barré syndrome; 8 cases with encephalitis have been reported [14] | 2.4% (5/206) with large-vessel stroke, Singapore [2] 5.3% (4/76) with neuromuscular symptoms, Taiwan [5] | 9.1% (5/55) with severe neurological symptoms, Iran [4] |
Onset of Neurologic manifestations | Can be both early and late onset of neurological manifestations [3] | Within 7 days | |
Common neurological manifestations in severe cases | Impaired consciousness; Acute cerebrovascular disease, Skeletal muscle injury | Polyneuropathy, encephalitis, and aortic ischemic stroke | Seizures, encephalopathy and encephalitis |
Prognosis | More patients have neurologic disorders in severe subtype with poor outcome | Poor | More children than adults were identified to have neurologic injury with poor outcome [7] |
Possible mechanism | The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure [11] | ACE2 [11] and immune injury may play a role | Direct infection, hypoxia and metabolite dysfunction may be more significant [12] |